NASDAQ
22.01.25
21:54 Uhr
0,545 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.01. | Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares | 11 | MarketBeat | ||
| 06.12.24 | Athira Pharma, Inc.: Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND | 165 | GlobeNewswire (Europe) | BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 08.11.24 | Athira exploring strategic alternatives after Alzheimer's failure | 10 | BioPharma Dive | ||
| 08.11.24 | Athira Pharma GAAP EPS of -$0.75 misses by $0.04 | 2 | Seeking Alpha | ||
| ATHIRA PHARMA Aktie jetzt für 0€ handeln | |||||
| 07.11.24 | Athira Pharma, Inc.: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | 137 | GlobeNewswire (Europe) | BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 07.11.24 | Athira Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.11.24 | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | 912 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen | |
| 18.10.24 | Athira Pharma faces Nasdaq delisting over share price | 7 | Investing.com | ||
| 18.10.24 | Athira Pharma, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 26.09.24 | Athira Pharma stock plunges to 52-week low of $0.41 | 1 | Investing.com | ||
| 26.09.24 | Athira Pharma-Aktie stürzt auf 52-Wochen-Tief von 0,41 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.09.24 | After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule | 2 | FierceBiotech | ||
| 19.09.24 | Athira Pharma stock faces pivot and workforce cuts amid trial setback - Mizuho | 1 | Investing.com | ||
| 18.09.24 | Athira Pharma-Aktie erreicht 52-Wochen-Tief bei 0,46 US-Dollar | 7 | Investing.com Deutsch | ||
| 17.09.24 | Athira Pharma, Inc.: Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases | 1 | GlobeNewswire (USA) | ||
| 17.09.24 | Athira Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09.24 | Athira Pharma stock plunges to 52-week low of $0.46 | 1 | Investing.com | ||
| 06.09.24 | Athira Pharma CEO sells over $2.8k in company stock | 1 | Investing.com | ||
| 06.09.24 | Athira Pharma COO Rachel Lenington sells shares worth $1,429 | 1 | Investing.com | ||
| 06.09.24 | Athira Pharma general counsel acquires shares, sells for $1.4k | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 2,304 | -4,48 % | InflaRx: Zulassung! | Die deutsche Biotech-Gesellschaft InflaRx kann einen wichtigen Meilenstein verbuchen. Denn die Europäische Kommission hat die Zulassung für Gohibic (Vilobelimab) zur Behandlung des SARS-CoV-2-induzierten... ► Artikel lesen | |
| COHERUS | 1,226 | -2,93 % | Coherus BioSciences, Inc.: Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | - Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate - - Antitumor... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,592 | -1,12 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to redefining the retina experience, today... ► Artikel lesen | |
| CHIMERIX | 3,775 | +4,14 % | Chimerix-Aktie erreicht 52-Wochen-Hoch bei 3,8 US-Dollar | ||
| CYTOMX THERAPEUTICS | 0,791 | -1,62 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update | - Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated... ► Artikel lesen | |
| SPERO THERAPEUTICS | 0,850 | +0,95 % | Spero Therapeutics, Inc.: Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes | Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 20,800 | 0,00 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza | SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies... ► Artikel lesen | |
| NEXTCURE | 0,742 | -3,89 % | NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers | BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 21,600 | -0,92 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results | Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June... ► Artikel lesen | |
| INSTIL BIO | 23,010 | +16,33 % | Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody | ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnco... ► Artikel lesen | |
| LAVA THERAPEUTICS | 0,900 | -2,70 % | LAVA Therapeutics N.V.: LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers | LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1 data read-out expected by year-end... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 41,620 | -0,90 % | Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein | Phase 1a results support further development of TX000045 ("TX45") for Group 2 Pulmonary Hypertension in HFpEF ("PH-HFpEF"), based on favorable pharmacokinetic profile and impact on renal plasma flow... ► Artikel lesen | |
| X4 PHARMACEUTICALS | 0,459 | -3,12 % | X4 Pharmaceuticals, Inc - S-8, Securities to be offered to employees in employee benefit plans | ||
| LENZ THERAPEUTICS | 24,290 | -0,49 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Third Quarter 2024 Financial Results | New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and... ► Artikel lesen | |
| BIOATLA | 0,492 | -1,70 % | BioAtla, Inc.: BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody | Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and... ► Artikel lesen |
ATHIRA PHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,545 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATHIRA PHARMA INC finden Sie auf Wallstreet Online.
